Dr Giuseppe d'Orsi — Top 1% Epilepsy

Dr Giuseppe d'Orsi is an expert in Neurology at Casa Sollievo della Sofferenza (Italy). As of October 2026, ScienceLeadR ranks Giuseppe d'Orsi in the top 1% of experts worldwide for Epilepsy. Giuseppe d'Orsi has authored 91 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 3 of them ongoing. SLR score: 375 (community average: 125). How the SLR is computed.

Neurology

Subspecialties: Genetics - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 19, 2026

Organizations

Career arc: 2011 - 2026

Source: PubMed

Casa Sollievo della Sofferenza

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 91

Citations

Citations: 1 521 1st author: 35 Last author: 9 Unique author: 1

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Empagliflozin in Lafora disease: A first-in-human 6-month pilot study with electroclinical and FDG-PET findings. PMID 42885669 — myoclonus, pilot projects, epilepsy, pilots, lafora disease, safety, myoclonic epilepsies, progressive	Epileptic Disord	2026
Familial prrt2-negative paroxysmal kinesigenic dyskinesia mimicking frontal lobe epilepsy: a video-eeg/polygraphic documentation. PMID 42825940 — epilepsy, dyskinesias, frontal lobe, epilepsy, frontal lobe, documentation, neurosciences	Neurol Sci	2026
Response to the Letter "Video-EEG biomarkers need a parallel delirium and medication timeline". PMID 42667204 — epilepsy, delirium, biomarkers	Epileptic Disord	2026
Correction: Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies. PMID 42583123 — drug resistant epilepsy, epilepsy, pharmacogenetics, pharmaceutical preparations, drug monitoring, precision medicine, therapeutics	Front Pharmacol	2026
Sustained seizure reduction, treatment simplification, and high retention with cenobamate: A 12-month real-world study in refractory and ultra-refractory focal epilepsy. PMID 42555196 — drug resistant epilepsy, epilepsy, pharmaceutical preparations, epilepsies, partial, seizures, therapeutics, retention, psychology	Epilepsia Open	2026

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2

N/A 1

Phase 2 1

By status:

Recruiting 3

Suspended 1

By type:

Interventional 4

By Monocentric/Multicentric:

monocentric 1

multicentric2to4 1

multicentric5to9 0

multicentricup10 2

Main Topics

Nervous System Diseases 1

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Efficacy and Safety Study of Once Daily Extended Release Levetiracetam in Drug resistant Focal Onset Seizures 2024-514499-42-00 — epilepsy, safety, pharmaceutical preparations, levetiracetam, seizures, therapeutics	Phase 3	Recruiting	2025
Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis A multicenter randomized placebo controlled and biological endpoints clinical Trial 2024-518888-35-00 — cells, sclerosis, neural stem cells, microscopy, electron, scanning transmission, stem cells, amyotrophic lateral sclerosis, therapeutics	Phase 2	Recruiting	2024
MiCrobiota gut brain Axis in Resistant Epilepsy NCT07010445 — drug resistant epilepsy, vagus nerve stimulation, epilepsy, pharmaceutical preparations, brain, diet, diet, ketogenic, diagnosis, gastrointestinal microbiome, microbiota	N/A	Recruiting	2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice

Giuseppe d'Orsi